No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)

Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in...

Descripción completa

Detalles Bibliográficos
Autores principales: Capelli, Laura, Casadei Gardini, Andrea, Scarpi, Emanuela, Frassineti, Giovanni Luca, Saragoni, Luca, Puccetti, Maurizio, Scartozzi, Mario, Giannini, Massimo, Tamberi, Stefano, Corbelli, Jody, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122846/
https://www.ncbi.nlm.nih.gov/pubmed/27886225
http://dx.doi.org/10.1038/srep37621
Descripción
Sumario:Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2–4) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer.

Ejemplares similares